NewLimit’s Discovery Engine uses functional genomics and machine learning models to test thousands of reprogramming interventions per experiment.
In each experimental cycle, we delivery thousands of unique reprogramming factor combinations to cells, profile cells with single cell multi-omics, and use machine learning models to infer how reprogramming impacts function. We then validate the most promising interventions with a suite of functional assays.
Our Engine employs machine learning models to intelligently select the interventions we explore. Rather than randomly searching all possible combinations, we use our knowledge of reprogramming factor biology and the results of each experiment to help select the next set of experiments we perform. Each experimental cycle helps improve those that follow.
The cells of your body possess the same DNA code, but epigenetic instructions determine which pieces of the code are used to perform the cell’s function. With age, the epigenetic landscape can change, reducing cell function and regenerative potential.
We can reprogram the epigenome to restore the instructions that each cell had when we were young. Nature has already created complex molecular machines that can achieve this task, and biotechnology now allows us to design entirely new epigenetic reprogramming tools from first principles.
Each cell is unique, but traditional tools have failed to resolve those differences. Single cell genomics now allows us to measure rich molecular profiles from millions of individual cells, unlocking previously intractable questions about the biology of epigenetic aging.
We combine single cell profiling with new cell reprogramming methods that take advantage of molecular barcoding and CRISPR technology to test thousands of hypotheses in a single experiment. This scale accelerates NewLimit’s discovery engine.
Performing many experiments is necessary, but not sufficient for the success of our mission. We need to determine the best possible experiments to extend our knowledge of aging biology and drive us toward effective medicines.
NewLimit uses machine learning models to prioritize our experimental efforts, ensuring that new experiments reveal new biology or improve our reprogramming interventions.
Taking advantage of NewLimit’s single cell genomics data, we are also developing models to perform informative experiments in silico, allowing us to interpret single cell profiles in terms of cellular age and function.
NewLimit is committed to increasing the number of healthy years in each human life. We'll do that by advancing the most imperative areas of the science of aging and formulating practical medicines along the way.